Neuronal nicotinic acetylcholine receptor alpha-4 beta-4 subtype (α4β4 nAChR)

The Neuronal nicotinic acetylcholine receptor alpha-4 beta-4 subtype is a pentameric ligand-gated ion channel composed of alpha-4 (CHRNA4) and beta-4 (CHRNB4) subunits. It belongs to the Cys-loop superfamily of receptors and is primarily expressed in the central nervous system, particularly in the medial habenula and interpeduncular nucleus, as well as in autonomic ganglia (Gotti et al., 2006, PMID: 17030136). This receptor facilitates fast excitatory neurotransmission and plays a significant role in modulating the release of other neurotransmitters such as dopamine, GABA, and glutamate. In clinical contexts, the alpha-4 beta-4 subtype is heavily implicated in the rewarding and reinforcing properties of nicotine, making it a key target for smoking cessation therapies (Wang et al., 2015, PMID: 25635022). Mutations in the constituent subunits have also been linked to certain forms of hereditary epilepsy, such as Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE). Pharmacological agents like varenicline and cytisine act as partial agonists at this and related subtypes to reduce nicotine cravings. Understanding the specific physiological role of the alpha-4 beta-4 subtype is essential for developing selective ligands that can treat neurological disorders while avoiding the peripheral side effects associated with broader nicotinic receptor activation (Zoli et al., 2015, PMID: 25446563).

Other names

CHRNA4/CHRNB4 receptoralpha4beta4 nicotinic receptornAChR alpha4beta4Neuronal acetylcholine receptor subunit alpha-4/beta-4 complex

Agonists bind to the extracellular interface of the alpha and beta subunits, inducing a conformational change that opens a cation-selective central pore. This allows the influx of sodium (Na+) and calcium (Ca2+) ions, leading to cellular depolarization and the subsequent activation of voltage-gated ion channels or the release of neurotransmitters (Albuquerque et al., 2009, PMID: 19144820). Antagonists act by either competing for the orthosteric binding site or by non-competitively blocking the ion pore itself.